Last update 28 May 2025

Pioglitazone Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione, 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione, pioglitazone
+ [38]
Target
Action
agonists
Mechanism
PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists)
Active Indication
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (15 Jul 1999),
RegulationOrphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H21ClN2O3S
InChIKeyGHUUBYQTCDQWRA-UHFFFAOYSA-N
CAS Registry112529-15-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
United States
15 Jul 1999
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hearing Loss, SensorineuralPhase 3
Czechia
24 Feb 2018
Hearing Loss, SensorineuralPhase 3
Germany
24 Feb 2018
Hearing Loss, SensorineuralPhase 3
Switzerland
24 Feb 2018
Alzheimer DiseasePhase 3
United States
01 Aug 2013
Alzheimer DiseasePhase 3
Australia
01 Aug 2013
Alzheimer DiseasePhase 3
Germany
01 Aug 2013
Alzheimer DiseasePhase 3
Switzerland
01 Aug 2013
Alzheimer DiseasePhase 3
United Kingdom
01 Aug 2013
Mild cognitive disorderPhase 3
United States
01 Aug 2013
Mild cognitive disorderPhase 3
Australia
01 Aug 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Early Phase 1
14
hcnrigrbat(zflwnixoxc) = pprgqbdoog kdnxxepbzi (dwgqnssquf, 0.9)
-
30 Apr 2025
Phase 4
26
(2000-200 Study 10-day Pioglitazone)
amzfzaxbcg(lfmhxnolxr) = lpjunpqzgl asypfpkdic (jxiybitnnd, 0.19)
-
03 Mar 2025
placebo+pioglitazone
(2000-200 Study 10-day Placebo)
amzfzaxbcg(lfmhxnolxr) = fybkutyooy asypfpkdic (jxiybitnnd, 0.20)
Phase 4
350
vvhhpujqbi(piiuzmdqia) = no significant difference in the CRP reduction was observed between the two groups rgjolzxumz (zjcacgpgbj )
Negative
06 Sep 2024
Placebo
Phase 4
318
tabxlvkisb(rhlyszsper) = itvfexcfos shamtxbwaq (lxknerxhtn, 0.1)
-
05 Sep 2024
(Conventional Therapy)
tabxlvkisb(rhlyszsper) = awotjfkuoe shamtxbwaq (lxknerxhtn, 0.1)
Phase 3
366
rutnjwifyj(qwckuqynzi) = tefpebqwjj abiqpgqkac (iwjpdcotks )
Positive
01 Jul 2024
rutnjwifyj(qwckuqynzi) = owrmszlfnh abiqpgqkac (iwjpdcotks )
Not Applicable
-
gjqrvddnef(yzjpyokjcz) = vgbznnjftc uojlvthswn (rwhsrvitev, 0.18)
-
14 Jun 2024
gjqrvddnef(yzjpyokjcz) = ebssdfjrxs uojlvthswn (rwhsrvitev, 0.11)
Phase 3
Polycystic Ovary Syndrome
HOTAIR rs1443512 genotype
65
nepzjmetjy(nmsdpmllvu) = kdidlvyuvs yhdxmczmaf (ztqdzsrvjt )
-
01 Apr 2024
Phase 3
249
noffdzqzdg(njmxhfqsbf) = Pioglitazone administration resulted in a significant reduction in HbA1c levels (from 7.80% ± 0.72% to 7.27% ± 0.82%) compared with placebo (from 7.79% ± 0.76% to 7.69% ± 0.86%, corrected mean difference: -0.42% ± 0.08%; p < 0.01). iyyqmfjhif (oblsykownj )
Positive
29 Feb 2024
Phase 4
343
ohwzkhxamx(gfkbhlurci) = ozgthvxzcf ezmvmsstjy (knqgizcvuw )
Negative
04 Oct 2023
Placebo
ohwzkhxamx(gfkbhlurci) = kghgghdhxb ezmvmsstjy (knqgizcvuw )
Phase 3
Polycystic Ovary Syndrome
HOTAIR rs1443512 genotype -
24
Pioglitazone 7.5 mg/d
zcwsbylenq(kplmptubvh) = exwzbozrjr udmvzzuepn (gjdmysbmio, 0.4)
Positive
21 Sep 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free